Cure MSA

Country specific patient information



Prof. Dr. Werner Poewe
Innsbruck Medical University
Department of Neurology
Anichstrasse 35
6020 Innsbruck, Austria

Prof. Dr. Gregor Wenning
Innsbruck Medical University
Department of Neurology
Anichstrasse 35,
A-6020 Innsbruck

Dr. Susanne Duerr
Innsbruck Medical University
Department of Neurology
Anichstrasse 35,
A-6020 Innsbruck

Email Contact: office(at)

Expertise of the participating organization:

The group has a long time involvement of the clinical assessment and the medical treatment of patients suffering from MSA and other patients with parkinsonism. It is the painful experience of non-responsive and steadily deteriorating MSA patients that drives the Innsbruck group to coordinate the first international collaboration on MSA in order to pave the way towards effective pharmacological intervention in this disorder.
Professor Werner Poewe will coordinate the project from the University Hospital Innsbruck, Professor Gregor Wenning will serve as head of the coordinating office. Professor Werner Poewe has considerable experience with the management of academic concertations. He currently holds the position of president of the Movement Disorders Society (MDS) and coordinates 2 MDS topical task forces. Furthermore, he has coordinated numerous international drug trials. Prof. Gregor Wenning is deeply involved in the care of parkinsonian patients. Since 1992 he has reported clinicopathological features of MSA patients in several important publications. Furthermore, he has designed the first pilot experiments towards a neural transplantation model of MSA.

Recent publications relevant to the EMSA-SG:

Kollensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, et al. Red flags for multiple system atrophy. Mov Disord 2008.


Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008; 210: 421-7.


Kollensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, et al. Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 2007; 22: 1771-6.


Kollensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, Del Sorbo F, et al. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 2007; 14: 66-72.


Kollensperger M, Stefanova N, Reindl M, Poewe W, Wenning GK. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. Mov Disord 2007; 22: 353-8.


Stefanova N, Kollensperger M, Hainzer M, Cenci A, Poewe W, Wenning GK. High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. Mov Disord 2007; 22: 969-73.


Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006; 21: 179-86.


Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, Mair KJ, Esterhammer R, Kremser C, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006; 21: 847-52.


Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. Trends Neurosci 2005; 28: 501-6.


Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 2005; 20 Suppl 12: S67-76.


Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3: 93-103.


Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004; 19: 1391-402.